Druck Icon

Eckert & Ziegler: capital increase successfully concluded / clear oversubscription

Berlin, 4 February 2009 - The Berlin based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) has successfully concluded its capital increase for cash. The company has increased its capital stock by 19.3%. 628,633 shares were thereby placed at a subscription price of 5.00 EUR each. The subscription period for the shareholders ended on 3 February 2009. After registering and implementing the capital increase in the commercial register the capital stock amounts to 3,878,633 EUR, divided into 3,878,633 shares. After the completion of the securities prospectus the new shares will be permitted to be traded on the Frankfurt Stock Exchange (Prime Standard).

With the capital increase around 3.1 million EUR flow into the company that will be used for the recently announced purchase of the Braunschweig isotope specialists nuclitec GmbH. "The clear oversubscription in excess of 50% underlines the great trust investors have in the company and our business model", explained Dr Andreas Eckert, Chairman of the Board at Eckert & Ziegler AG. The capital increase, was accompanied by BankM - representation of biw Bank für Investments und Wertpapiere AG.

Eckert & Ziegler AG, which achieved a turnover of approx. 70 million EUR in 2008 with around 410 employees, is one of the world's largest providers of isotopic components for radiation therapy and nuclear medicine.

The Board of Directors